2019-12-13 09:32:00 Fri ET
stock market gold oil stock return s&p 500 asset market stabilization asset price fluctuations stocks bonds currencies commodities funds term spreads credit spreads fair value spreads asset investments
Saudi Aramco aims to initiate its fresh IPO in December 2019. Several investment banks indicate to the Saudi government that most investors may value the middle-east oil company at the target range of $1.5 trillion to $1.7 trillion. This current stock market valuation falls shorts of the prior $2 trillion benchmark that the crown prince Mohammed bin Salman anticipated in his first Saudi Aramco IPO announcement back in 2016.
As the most profitable state oil enterprise, Saudi Aramco is worth almost twice the equity valuation of Apple (which leads almost all U.S. public corporations in terms of stock market capitalization). Further, Saudi Aramco earns more than the overall net income of the other top international oil companies (ExxonMobil, Royal Dutch Shell, BP, and Chevron).
The prince expects to funnel the Saudi Aramco IPO proceeds into a new sovereign wealth fund that helps the middle-east kingdom wean the fragile Saudi economy off its long-run reliance on oil production. The sovereign wealth fund can empower Saudi Arabia to diversify across numerous new industries such as Internet search, mobile pay, artificial intelligence, robotic automation, semiconductor technology, and cloud computation etc. This diversification helps minimize the primary national security threat to Saudi Arabia.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2023-09-14 09:28:00 Thursday ET
Colin Camerer, George Loewenstein, and Matthew Rabin assess the recent advances in the behavioral economic science. Colin Camerer, George Loewenstei
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be
2025-06-05 00:00:00 Thursday ET
Former New York Times team journalist and Pulitzer Prize winner Charles Duhigg describes, discusses, and delves into how we can change our respective lives
2019-01-02 06:28:00 Wednesday ET
New York Fed CEO John Williams listens to sharp share price declines as part of the data-dependent interest rate policy. The Federal Reserve can respond to
2017-12-09 08:37:00 Saturday ET
Michael Bloomberg, former NYC mayor and media entrepreneur, criticizes that the Trump administration's tax reform is a trillion dollar blunder because i
2019-09-09 20:38:00 Monday ET
Harvard macrofinance professor Robert Barro sees no good reasons for the recent sudden reversal of U.S. monetary policy normalization. As Federal Reserve Ch